Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Tara Graff, DO

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

Now Viewing

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Video content above is prompted by the following:

Provide an overview of the following emerging BTKi treatment regimens in treatment-naive patients with MCL.

Acalabrutinib + bendamustine + rituximab
Acalabrutinib + lenalidomide + rituximab
Acalabrutinib + umbralisib + ublituximab
Ibrutinib + rituximab
Zanubrutinib + rituximab